(Q36668246)

15 August 2017

1 reference

title

Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates (English)

1 reference

15 August 2017

1 reference

2

Evanthia Galanis

1 reference

15 August 2017

Lijo Simpson

1

1 reference

15 August 2017

1 November 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

1593-1607

1 reference

15 August 2017

11

1 reference

15 August 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Chemotherapy for high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Recent advances in the molecular genetics of primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Altered molecular pathways in gliomas: an overview of clinically relevant issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Molecular changes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Capillary permeability in experimental rat glioma and effects of intracarotid CDDP administration on tumor drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Anaplastic oligodendroglial tumors: a tale of two trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Mechanisms of angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Angiogenesis in gliomas: biology and molecular pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Modulation of radiation response by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The ubiquitin-proteasome pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Gene expression profiling and genetic markers in glioblastoma survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The role of integrins in the malignant phenotype of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Mutations in the p53 gene occur in diverse human tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The p53 gene and its role in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease–substrate interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Immunobiology of gliomas: new perspectives for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Tenascin expression in human glioma cell lines and normal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Dynamic magnetic resonance perfusion imaging of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Convection-enhanced delivery in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.11.1593

10.1586/14737140.6.11.1593

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17134364